Company Description
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States.
The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data.
The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.
KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jul 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Avi Minkowitz |
Contact Details
Address: 1167 Massachusetts Avenue Arlington, Massachusetts 02476 United States | |
| Phone | 781 996 5252 |
| Website | kalarx.com |
Stock Details
| Ticker Symbol | KALA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479419 |
| CUSIP Number | 483119301 |
| ISIN Number | US4831193010 |
| Employer ID | 27-0604595 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Avi Minkowitz | Chief Executive Officer, Chief Financial Officer and Director |
| Mary Reumuth CPA | Treasurer and Secretary |
| Dr. Justin Hanes Ph.D. | Founder and Chair of the Scientific Advisory Board |
| Jill S. Steier | Executive Director of Investor Relations and Corporate Communications |
| Vincent Kosewski | Senior Vice President of Manufacturing and Supply Chain Management |
| Dr. Francis S. Mah M.D. | Chief Medical Advisor |
| Carl Rennie | Executive Director of Account Management |
| Patrick Bedell | Executive Director of Trade and Alternate Channels |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2026 | EFFECT | Notice of Effectiveness |
| Jun 12, 2026 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 7, 2026 | 8-K | Current Report |
| Apr 15, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 17, 2026 | D | Notice of Exempt Offering of Securities |
| Mar 17, 2026 | 144 | Filing |